(Source: Amgen Inc) THOUSAND OAKS, Calif., May 19, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced it will present new data from its oncology portfolio at the 21Congress of the European Hematology Association (EHA), June 9-12, 2016, in Copenhagen. Key data to be presented include studies evaluating BLINCYTO(blinatumomab), Kyprolis (carfilzomib), Aranesp (darbepoetin alfa) and Nplate (romiplostim). Data from the BLINCYTO TOWER study will be presented during the Presidential Symposium on Friday, June 10, and is recognized as a top abstract submitted to the Congress. This, along with other presentations, reinforces Amgen's commitment to serve patients with hematologic malignancies...
↧